Treatment of patients with advanced colorectal cancer with bermekimab (a monoclonal antibody against IL-1α) was found to significantly improve the clinical response rate (phase III, NCT01767857), and nadunolimab (a monoclonal antibody against IL-1 receptor accessory protein (IL1RAP)) in combination with nab-paclitaxel and gemcitabine demonstrated a clinical benefit rate of 74% (phase I/IIa, NCT03267316) [134]. This evidence concerns the gene IL1RAP and colorectal cancer.